InterMune Files NDA For IPF Drug Despite Mixed Pivotal Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
With IPF currently an unmet medical need in the U.S.; company seeks priority review; drug marketed in Japan by partner Shionogi.